Sclerosis drug developed by Genmab brings in USD 66m to Novartis during Q2

The launch of sclerosis treatment Kesimpta is continuing to go well for Novartis, which has exceeded its financial expectations for the second quarter of this year.

Photo: CHARLES PLATIAU/Reuters / X00217

During Q2, sclerosis treatment Kesimpta brought in USD 66m to Novartis, the company financial report released on Wednesday states.

Kesimpta is far from the biggest treatment in Novartis' portfolio - Cosentyx, a psoriasis treatment, took that title in Q2 - but is nonetheless a growing asset for the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs